Last Updated : May 3, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Zytram XL | Tramadol hydrochloride | Pain, acute | Withdrawn | |||
| N/A | imiquimod | Gynecological cancers | Withdrawn | |||
| Mifegymiso | Mifepristone and misoprostol | Medical termination of pregnancy (gestational age up to 49 days) | Withdrawn | |||
| Praxbind | Idarucizumab (Drug Plan Submission) | Reversal of dabigatran anticoagulant effects | Withdrawn | |||
| Venclexta | Venetoclax | Withdrawn | ||||
| Adcetris | Brentuximab vedotin | Withdrawn | ||||
| Adcetris | brentuximab vedotin | Hodgkin lymphoma | Withdrawn | |||
| Winlevi | clascoterone | Acne vulgaris | Withdrawn | |||
| Alsitek | masitinib mesylate | Amyotrophic lateral sclerosis (ALS) | Suspended | |||
| Isturisa | osilodrostat | Endogenous Cushing’s syndrome | Suspended |
Last Updated : May 3, 2024